# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on Eli Lilly with a price target of $885. Eli Lilly's...
Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly and Co (NYSE:LLY) with a Overweight and maintains $885 price target.
Pfizer has selected its preferred once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, with...
EMA advises patients on GLP-1 weight-loss drugs like Wegovy to inform their doctors before surgery due to potential respiratory...
Novo Nordisk has found that its diabetes drug, Ozempic, is linked to a significant reduction in the risk of dementia and other ...
Shares of Eli Lilly and Co (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) are facing declines Thursday, maybe influenced by compe...
Senator Bernie Sanders is pushing Novo Nordisk to lower U.S. prices for weight-loss drugs Ozempic and Wegovy, as part of a broa...